The role of bone marrow transplantation in acute promyelocytic leukemia

Citation
C. Nabhan et al., The role of bone marrow transplantation in acute promyelocytic leukemia, BONE MAR TR, 28(3), 2001, pp. 219-226
Citations number
66
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Journal title
BONE MARROW TRANSPLANTATION
ISSN journal
02683369 → ACNP
Volume
28
Issue
3
Year of publication
2001
Pages
219 - 226
Database
ISI
SICI code
0268-3369(200108)28:3<219:TROBMT>2.0.ZU;2-O
Abstract
Acute promyelocytic leukemia (APL) is characterized by a specific gene rear rangement and the generation of the PML-RAR alpha fusion transcript which r esults from a translocation between chromosomes 15 and 17. Targeted therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy r esults in an apparent cure in 70-80% of patients. Both allogeneic (ALLO) an d autologous (AUTO) hematopoietic stem cell transplantation (HSCT) are effe ctive in acute myeloid leukemia (AML), but their role in APL is not clear g iven the excellent outcome with ATRA and chemotherapy. Several retrospectiv e studies have analyzed the outcome of patients undergoing AUTO or ALLO-HSC T in first (CRI) or second (CR2) complete remission. Most of these studies have shown significant transplant-related mortality (TRM) with ALLO-HSCT, b ut a reduction in relapse rate compared with AUTO-HSCT. The high TRM with A LLO-HSCT and the excellent outcome with ATRA and chemotherapy do not justif y recommending this procedure for the majority of patients in CRI. The role of AUTO-HSCT in CRI also is unclear. A small subset of patients at high ri sk of relapse, possibly identifiable by a high white blood cell count at pr esentation may benefit from HSCT. Most patients with relapsed disease achie ve CR2 with ATRA, arsenic trioxide, or combination therapy. However, it is not known if these responses are sustained or if consolidation with HSCT ha s a place in this setting. The outcome of AUTO-HSCT in CR2 using stem cells that are negative for PML-RAR alpha is excellent. It is unclear whether AL LO-HSCT from an HLA-identical sibling is superior to AUTO-HSCT with PML-RAR alpha -negative cells in CR2 since the former would be associated with gra ft-versus-leukemia effects and the latter with lower TRM. Alternatively, ar senic trioxide or re-treatment with ATRA, followed by intensive chemotherap y may also be effective. A randomized prospective clinical trial, or a retr ospective analysis of the available data would be useful in answering this critical question.